Asthalin Expectorant is used in situations involving certain distressing symptoms related to physical discomfort and is applied across domains where additional symptomatic support is needed. This combination is considered relevant in contexts involving heightened systemic burden related to the respiratory system. It helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

The medicine is commonly used across conditions presenting with acute episodes, relevant in situations involving recurrent or episodic manifestations. These therapeutic areas generally involve conditions where symptoms may intensify temporarily, such as those related to inflammatory or irritative states. It is applied in clinical settings that involve acute or unstable symptom patterns, particularly when symptoms lead to noticeable physiological strain.

“It assists in managing symptoms that interfere with daily comfort.”

It helps to ease the overall symptom burden and supports general well-being during symptomatic phases.

---

Quick Fact: Supports the management of symptoms linked to heightened physiological activity

Regulatory References

1. Philippine FDA Product Information

Who Can and Cannot Use Asthalin Expectorant?

The population eligibility for Asthalin Expectorant (Salbutamol and Guaifenesin oral solution) is strictly defined by regulatory authorities based on contraindications and specific risk factors.

Absolute Contraindications

Use is strictly prohibited for patients with a known hypersensitivity or allergy to Salbutamol, Guaifenesin, or any other ingredients in the formulation. It is also contraindicated in patients with severe thyrotoxicosis (overactive thyroid) and must not be used to treat threatened abortion or premature labour.

---

Conditional Use and Restrictions

Specific caution is required for individuals with certain pre-existing conditions, as mandated by regulatory labeling. These include cardiovascular disorders (such as cardiac arrhythmias and hypertension), diabetes mellitus, and convulsive disorders.

---

Age and Physiological Limitations

Asthalin Expectorant is not recommended for children below two years of age because safety and effectiveness in this infant population have not been established. Use in nursing mothers is generally not recommended unless the expected benefit outweighs potential risk. Caution is also advised in patients with severe renal impairment or hepatic impairment.

Interactions with other medicines and products

The interaction profile for Asthalin Expectorant is defined by regulatory restrictions and warnings related to both active components, Salbutamol and Guaifenesin. All factual statements are based on authoritative government regulatory documents.

Interaction Scope and Classification The most significant interaction restriction is the prohibition against co-administration with non-selective beta-receptor blocking drugs, such as Propranolol. Regulatory documents classify this combination as one that should not usually be prescribed together due to the risk of severe pharmacodynamic antagonism leading to bronchoconstriction.

The Salbutamol component carries warnings for pharmacodynamic potentiation when used with certain drug classes. Concomitant use with Diuretics (non-potassium-sparing), Xanthine Derivatives, and Corticosteroids may potentiate the risk of hypokalemia. Additionally, co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) may potentiate the effect of Salbutamol on the vascular system.

An exposure modification interaction is noted with the cardiac glycoside Digoxin, where co-administration may decrease serum Digoxin levels. No formal timing separation rules are specified.

The Guaifenesin component has a procedural constraint: its metabolite may cause color interference with laboratory determinations of urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Connection to the overall interaction profile Regulatory documents define the product's interaction structure around the risk of antagonistic or additive pharmacodynamic effects and the alteration of Digoxin exposure. This profile guides the mandated restrictions and monitoring requirements for co-administered therapies.

How Asthalin Expectorant Works

beta2-Receptor Agonism and Airway Relaxation

The mechanism of action involves a dual influence on the respiratory system. One component functions as an agonist by selectively binding to Beta-2 adrenergic receptors on the bronchial smooth muscles. This interaction initiates an intracellular molecular cascade that results in the relaxation of these muscle fibers, leading to the establishment of a greater bronchial lumen diameter.

---

Modulation of Respiratory Secretions

The second component acts as a secretagogue, influencing the mucociliary clearance system. This mechanism modulates the output of mucus-secreting glands, modifying the thickness and volume of the respiratory tract secretions. The resulting physiological change renders the secretions thinner and less viscous, promoting the transport and clearance of material from the lower airways.

---

Integrated Physiological Modulation

These two distinct mechanistic domains—the modulation of muscle tone and the alteration of secretion properties—operate simultaneously. Their combined effect establishes a comprehensive physiological modulation of airway mechanics, affecting both the dimension of the air passages and the efficiency of material removal from the respiratory tract.

How to Use Asthalin Expectorant: Administration Guidelines

Asthalin Expectorant, an oral combination product containing Salbutamol and Guaifenesin, is administered strictly by the oral route as a liquid solution (syrup). Adherence to the prescribed volume and frequency is essential, as the dose and schedule are fixed based on established specifications.

---

Dosing and Frequency

Administration follows a fixed intermittent schedule, typically two or three times daily, reflecting the short duration of action of the bronchodilator component. The liquid must be shaken well before use, and the correct volume must be accurately measured using a calibrated device.

Population Group	Labeled Dose Volume (per administration)	Frequency Pattern
Adults (Over 12 years)	10 mL to 20 mL	2 or 3 times daily
Children 6 to 12 years	10 mL	2 or 3 times daily
Children 2 to 6 years	5 mL to 10 mL	2 or 3 times daily

---

Administration Context and Procedural Rules

The medicine offers flexibility in timing and may be taken with or without food. For older adults or individuals known to be unusually sensitive, treatment should be initiated at the lower end of the adult dose, specifically 10 mL. A key constraint is that the dosage or frequency of administration must not be increased without explicit medical advice. This rule reinforces the importance of using the drug strictly as prescribed and avoiding unauthorized dose escalation.

Overview of Research and Dual Action

The research base for this combination of Salbutamol and Guaifenesin includes short-term studies on the specific formulation and data from extensive pharmacological studies on the individual components. Research examines the principles of bronchodilation and mucus clearance, often in contexts involving temporary physiological imbalance. The evidence contributes to the broader landscape related to conditions characterized by fluctuating or episodic respiratory symptoms.

---

Evidence for Use in Productive Cough and Airway Obstruction

Research has been conducted exploring the combination’s evaluation in patients experiencing a productive cough accompanied by restricted airflow. These investigations primarily involve short-term Randomized Controlled Trials (RCTs) and Comparative Studies. Researchers monitored patient outcomes such as cough frequency and sputum tenacity, alongside physician or patient global assessments of condition status. Research often explored study outcomes by comparing the combination against single-component treatments, rather than consistently including an inactive substance (placebo).

---

Research Gaps and Follow-Up Duration

Studies conducted generally have short follow-up durations, typically measuring changes over just 4 to 7 days. Long-term effects are not fully established, and evidence is limited regarding the effects when research examines administration over extended, non-episodic periods. Data for certain groups, such as those who are pregnant or breastfeeding, remain limited, and research understanding is frequently based on established data for the individual components.

---

Key Limitations and Uncertainty

Scientific literature indicates that study methodology and design varies across studies, with findings sometimes being mixed. Comparative evidence, which would assess the combination against other established treatments (such as inhaled therapies), is often lacking. This combination product's evidence base contributes to the broader evidence landscape, but certainty remains low in some areas, and new data are still emerging.

Key Studies & References

1. Systematic review of randomized controlled trials of over the counter cough medicines for acute cough in adults
2. Cough (acute): antimicrobial prescribing - Summary of the evidence (NICE Guideline NG120)
3. Analysis of the evidence of efficacy and safety of over-the-counter cough medications registered in Brazil (Review noting lack of FDC trials)
4. Salbutamol (Albuterol) - WHO Essential Medicines List (eEML) Listing
5. Product Information: Salbutamol (as sulfate) + Guaifenesin (Ventolin Expectorant, Example of FDC Regulatory Status)

Common questions about Asthalin Expectorant (FAQ)

---

Q: How quickly can I expect Asthalin Expectorant to start working?

Regulatory documents indicate that the bronchodilator component is generally characterized as having a rapid onset of action. Its effects may typically begin within a few minutes after administration. This rapid action is described as characteristic of this type of medicine.

---

Q: How long do the effects of Asthalin Expectorant usually last?

Official documents indicate that the bronchodilator component is considered short-acting. Its effects are generally described as lasting for a period of four to six hours, which aligns with the typical dosing frequency cited in product information.

---

Q: What are the most commonly reported side effects of Asthalin Expectorant?

Based on regulatory documentation, the most frequent adverse events listed are fine skeletal muscle tremor (a common type of shaking), headache, and cardiovascular effects such as palpitations and increased heart rate. These effects are often observed early in treatment or following a dose adjustment.

---

Q: Is it common to feel jittery or shaky after taking Asthalin Expectorant?

Yes, fine skeletal muscle tremor is listed in regulatory documents as a 'Very Common' side effect, affecting more than 1 in 10 users. This sensation of feeling shaky or jittery is often related to the bronchodilator component of the medicine.

---

Q: Can Asthalin Expectorant be taken with common cold and flu medicines?

Official documents caution against taking this medicine with certain drug classes due to the potential for interactions. It is important to review common cold and flu medicines for ingredients like other sympathomimetics or central nervous system (CNS) depressants, as official documents caution against certain combinations.

---

Q: Is Asthalin Expectorant known to cause drowsiness or affect alertness?

Official regulatory documents indicate that the medicine may cause dizziness or sleepiness in some individuals. Patients are advised of the potential for decreased alertness while using the product.

---

Q: Is there any research evidence available on the general effectiveness of Asthalin Expectorant?

Research has been conducted on the combination product’s evaluation in patients experiencing productive cough accompanied by restricted airflow. These findings contribute to the broader evidence base related to managing these specific respiratory symptoms.

---

Q: Is it normal to experience a dry mouth while using Asthalin Expectorant?

While not explicitly listed as a 'Very Common' or 'Common' side effect in the official product documents, dryness of the mouth is a commonly reported effect associated with the use of similar respiratory medicines.

---

Q: Can children use Asthalin Expectorant, and are there age restrictions?

Official product information states the medicine is labeled for use in children from two years of age and older. Specific use guidelines apply for different pediatric age groups. It is not recommended for children below two years of age because safety and effectiveness in this infant population have not been established.

---

Q: Are there any studies regarding the long-term use of Asthalin Expectorant?

Scientific literature indicates that studies generally have short follow-up durations, typically measuring changes over less than one week. Official information indicates that evidence is limited regarding effects when administration is examined over extended, non-episodic periods.

---

Q: Can Asthalin Expectorant cause problems with sleep?

The medicine may cause side effects, such as increased heart rate (tachycardia) and fine skeletal muscle tremor (shaking), that could potentially interfere with normal rest and sleep patterns. These effects are often related to the stimulant properties of the bronchodilator component.

---

Q: Is it okay to use Asthalin Expectorant if I have diabetes?

Caution is advised in individuals with pre-existing conditions such as diabetes mellitus. The Salbutamol component is associated with metabolic effects and may lead to hyperglycemia, which is an increase in blood sugar levels.

---

Q: What is the official information regarding use of Asthalin Expectorant during pregnancy?

Regulatory documents state that use during pregnancy is generally restricted unless the prescribing doctor determines that the medical benefit is considered to clearly outweigh the potential risks. Official guidelines also note the medicine must not be used to treat threatened abortion or premature labour.

---

Q: Is Asthalin Expectorant safe to use while breastfeeding?

Use in nursing mothers is generally not recommended, according to official information, unless the expected benefit outweighs the potential risk. This approach is taken because safety and efficacy data for this population are limited.

---

Q: Is Asthalin Expectorant the same as a regular cough syrup?

Asthalin Expectorant is classified in regulatory documents as a 'Sympathomimetic Bronchodilator' and an 'Expectorant' due to its two active components. This dual classification means it is intended for both airway constriction and mucus clearance, differentiating it from simple, single-action cough remedies.

---

Q: Are there certain foods or drinks I should avoid while taking this expectorant?

Official guidelines state the medicine may be taken with or without food. However, co-administration with alcohol is cautioned against in official documents. This is due to the potential for additive side effects like increased dizziness or sleepiness.

---

Q: Are there any specific safety precautions listed for people with heart conditions using Asthalin Expectorant?

Caution is advised for individuals with certain cardiovascular disorders, such as hypertension or irregular heartbeat. Regulatory profiles may require the monitoring of serum potassium levels in specific scenarios due to the medicine's documented effects on the cardiac system.

---

Q: Are there any known interactions between Asthalin Expectorant and alcohol?

Official documentation advises caution against or limiting the consumption of alcohol. This is because alcohol may increase the risk of certain side effects such as sleepiness, dizziness, or impaired judgment when combined with this product.

---

Q: Is this medicine suitable for patients with a persistent dry cough?

Official indications state that this combination product is generally used for conditions involving a productive cough, meaning one that produces mucus or phlegm, alongside restricted airflow. Its components are designed to help clear viscous secretions.

---

Q: Are there official warnings about operating machinery while using Asthalin Expectorant?

Yes, official warnings advise caution when driving or operating heavy machinery. This is due to the potential for the medicine to cause dizziness or sleepiness, which could impair a person's judgment and reactions.

---

Q: What should I do if I miss a scheduled amount of Asthalin Expectorant?

Official guidelines describe that if a scheduled dose is missed, the recommended procedure is to take it as soon as it is remembered. However, if the time is close to the next scheduled dose, official guidelines indicate that the missed dose should be skipped. The dose must not be doubled.

---

Q: Why do some people confuse Asthalin Expectorant with inhalers?

The confusion may arise because Asthalin Expectorant contains Salbutamol. This is the same active bronchodilator ingredient commonly found in the liquid used in metered-dose inhalers or nebulizers, although the delivery method (oral vs. inhaled) is different.

---

Q: Does Asthalin Expectorant contain any antihistamines?

No. The medicine's composition is based on two essential active ingredients: Salbutamol Sulfate, which acts as a bronchodilator, and Guaifenesin, which acts as an expectorant. Antihistamines are not listed as active components.

---

Q: Is it safe to double up on the medication if I feel worse?

Regulatory documents explicitly state that the dosage or frequency of administration must not be increased without explicit medical advice. The dose must not be doubled if symptoms are worsening.

---

Q: Does Asthalin Expectorant affect blood sugar levels?

Yes. The Salbutamol component is associated with metabolic effects, and official labeling notes that it may lead to hyperglycemia, which is an increase in blood sugar levels. This is why caution is advised for patients with diabetes.

Storage and Disposal Requirements

Asthalin Expectorant (Salbutamol/Guaifenesin Oral Solution) must be stored under specific conditions to maintain its stability and effectiveness, as mandated by regulatory labeling.

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), or below 30 C.
Protection	Keep the container tightly closed and protect from light, moisture, and excessive heat.
Safety	Keep the medicine out of the sight and reach of children.

Do not use the product after the expiration date. For disposal, unused or expired expectorant should not be flushed down the toilet or poured into a drain. It must be discarded using an official drug take-back program or by following recommended household disposal steps.